Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Pitcairn Co.

Pitcairn Co. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 962 shares of the biopharmaceutical company’s stock after purchasing an additional 44 shares during the quarter. Pitcairn Co.’s holdings in Regeneron Pharmaceuticals were worth $1,011,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $26,000. Sachetta LLC grew its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares in the last quarter. Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on REGN shares. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of Regeneron Pharmaceuticals stock opened at $738.00 on Monday. The stock has a market capitalization of $81.10 billion, a P/E ratio of 18.26, a PEG ratio of 2.84 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $945.07 and a two-hundred day moving average price of $1,027.53. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.